Key result
Higher cystathionine linked to ~70% greater odds of worse 90-day mRS per SD in AIS.
Why the study?
Stroke biology changes hour-by-hour, but biomarker studies typically sample blood daily at best, missing time-ordered signals.
Does hourly plasma multi-omics identify molecular trajectories and biomarkers associated with clinical outcomes in acute ischemic stroke?
Observational (n=504)
Does hourly plasma multi-omics identify molecular trajectories and biomarkers associated with clinical outcomes in acute ischemic stroke?
Effect estimate: OR 1.70 per SD
p-value: p=1.5×10-12
Hourly plasma multi-omics in acute ischemic stroke identifies time-resolved molecular trajectories and nominates cystathionine as a biomarker for infarct volume and 90-day functional outcome.
May flag higher-risk stroke patients for intensified monitoring; leaves open cystathionine as therapeutic target in acute ischemia.
Background and aims Stroke biology changes hour-by-hour, but biomarker studies typically sample blood daily at best - missing time-ordered signals. We tested whether hourly plasma multi-omics can uncover molecular trajectories aligned with clinical evolution and identify single-timepoint biomarkers. Methods We performed hourly plasma sampling from 1-48 hours after onset in two patients with acute large-vessel occlusion stroke for proteomics, metabolomics, and peptidomics. We used dimensionality reduction to capture temporal structure and an autoencoder to derive trajectory clusters with pathway enrichment. We quantified tissue contributions by mapping proteins/peptides to the Human Protein Atlas. Validation was conducted in an independent cohort (N=502, PROMISE). Results Hourly plasma multi-omics revealed time-ordered change and non-monotonic trajectory clusters (Fig. A-B), underscoring the need for hourly sampling for biomarkers with unknown kinetics. Despite similar baseline severity and reperfusion treatment, patient #1 exhibited molecular changes indicative of rising platelet/NETosis-related thromboinflammation and catabolic stress, whereas patient #2 displayed attenuated responses (Fig. C-E). These differences coincided with greater infarct-progression (final-infarct-volume: 146 vs 17ml), hemorrhagic transformation, and worse 90-day outcome in patient #1 (mRS 5 vs 3). Cystathionine (an intermediate to glutathione redox buffering) rose steadily in patient #1 but declined early in patient #2. In PROMISE (N=502), cystathionine correlated with infarct volume (ρ=0.19, p=2.3×10-5) and predicted worse 90-day mRS (OR=1.70 per SD, p=1.5×10-12). Conclusions Hourly plasma multi-omics maps clinically aligned, time-resolved stroke biology and nominates single-timepoint biomarkers. Scaling to larger cohorts will link trajectory clusters to tissue injury and outcomes, enabling early molecular stratification. Conflict of interest Ali Rezaei: nothing to disclose Figure 1 - belongs to Conclusions
No takes yet. Share an insight, caveat, or question.
Rezaei et al. (2026) conducted an observational in Acute ischemic stroke (n=504). Plasma multi-omics and cystathionine measurement was evaluated on 90-day mRS (OR 1.70 per SD, p=1.5×10-12). Higher cystathionine levels predicted worse 90-day functional outcomes (OR 1.70 per SD, p=1.5×10-12) in patients with acute ischemic stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: